Wells Fargo Maintains Overweight on Calumet, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Roger Read has maintained an Overweight rating on Calumet (NASDAQ:CLMT) and increased the price target from $25 to $29.
October 21, 2024 | 3:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has reaffirmed its Overweight rating on Calumet and increased the price target from $25 to $29, indicating a positive outlook.
The increase in price target from $25 to $29 by Wells Fargo suggests a positive outlook for Calumet, likely leading to a short-term price increase. The Overweight rating indicates confidence in the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100